Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain

Stopped early · Phase 3

Conditions studied: Pain, Cancer

In brief

The purpose of this study is to evaluate the safety of the matrix fentanyl patch ZR-02-01 in providing relief of cancer pain.

Key facts

Study ID

NCT00126789

Run by

ZARS Pharma Inc.

People needed

24

Starts

2005-08-01

Expected to finish

2007-07-01

Last updated by the study team

2012-06-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is at least 18 and no older than 75 years of age at the time of screening
• Patient has a diagnosis of cancer
• Patient has moderate to severe pain that is related to cancer or its treatment and is expected to last indefinitely and is currently taking an around-the-clock opioid to treat his/her pain
• Patient is already receiving opioid therapy, has demonstrated opioid tolerance
• A responsible adult caregiver is available in the event of an emergency at home

You may not qualify if…

• Patient has uncontrolled or rapidly escalating pain as determined by the investigator
• Patient has a history of substance abuse or has a substance abuse disorder

Where it is running

• Loma Linda Center for Pain Management — Loma Linda, California, United States
• The Center for Clinical Research — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.